biosimilars

I N D I A 2 0 1 0
Organised by:
Biogenerics Follow-on-Biologics Biobetters Biosuperiors
Early Bird Discounts!
Book before 30 July 2010

biosimilars
I N D I A 2 0 1 0 Ways to Register
Save INR.10,000 / US$200
Book before 3 September 2010
Save INR.5,000 / US$100

biosimilars
30 September – 1 October 2010 Online: www.biosimilars-india.com
“The ‘Made-in-India’ biosimilars market (domestic plus Le Royal Méridien Mumbai
Tel +91 (022) 4046 1466
export) was worth around $200 million in 2008, and is Sahar Airport Road, Andheri (East)
Mumbai 400 099, India Fax +91 (022) 4046 1477
expected to more than double to reach around Tel +91 (022) 2838 0000
$580 million by 2012” (Biospectrum) Early Early Bird!!
Book and pay by Friday 30 July 2010
Please
register
Indian Delegate @ INR30,000 +10.3% Service Tax = INR33,090
International Delegate @ US$1,195 +10.3% Service Tax = US$1,318.09
Email conferences@ubmindia.com

Post Conference Department,

Early Bird!
Book and pay by Friday 3 September 2010
Please
register
Indian Delegate @ INR35,000 +10.3% Service Tax = INR38,605
International Delegate @ US$1,295 +10.3% Service Tax = US$1,428.39


UBM India Pvt Ltd, Sagar Tech Plaza A, 
119, 1st Floor, Andheri Kurla Road,
I N D I A 2 0 1 0
Standard Rate Please Indian Delegate @ INR40,000 +10.3% Service Tax = INR44,120 Saki Naka Junction, Andheri East,

Dear Colleague,
register International Delegate @ US$1,395 +10.3% Service Tax = US$1,538.69 Mumbai, 400072, India.
Two-Day Strategic Conference Gain In-Depth
Delegate Details (for ease, please attach your business card ) - Please photocopy for additional bookings Guidance on:
CPhI Conferences is delighted to announce its 2nd Annual Biosimilars India 2010 conference.
Delegate Contact Details- PLEASE COMPLETE IN BLOCK CAPITALS
30 September – 1 October 2010 Regulation
Understanding the impact of
Building on the success of our 2009 conference, we bring you a revised and refreshed agenda
that deep dives into the most timely R&D, manufacturing and regulatory challenges facing the
Le Royal Méridien Mumbai, India WHO guidelines in respect to Indian and European
Title: First Name: Surname: regulatory frameworks
biosimilars industry today! Company Name:
Commercialisation
Evaluating the market opportunities, international
There is no denying that the global biosimilars opportunity for Indian manufacturers and allied Job Title: Department: partnerships and profitable outsourcing models
Research and Development
industries is enormous. However, to take full advantage of the rewards that await, you must be fully Address: Outstanding Overcoming the cloning, fermentation and purification
equipped and aligned to tackle the technical, commercial and regulatory challenges today. Tel: Fax: Email: Contributions from: complexities to maximise yield and commercial viability
By providing your email address you consent to being contacted by email for direct marketing purposes by UBM India Pvt. Ltd.
MK Sahib Gopal Dasika Manufacturing
Attend this intensive two-day strategic conference and prepare to take your biosimilars strategy to *I have read and agree with the terms and conditions.
Vice President, Biotechnology Achieving effective collaboration of R&D, process
Director Biotechnology
the next level. Just some of the issues that will be tackled at this conference include: Signature: Wockhardt Unichem Laboratories development and manufacturing functions
Line Manager: Job Title: Narasimham Jammi Cold Chain Management
• Regulatory Developments – understand the impact of local and international regulatory Steffen Denzinger Leveraging the latest cold chain distribution
Associate Director PC-SR Head Biotechnology
scenarios and the implications for your biosimilars strategy Secretary/PA: Tel: Shasun Chemicals and Drugs systems to ensure quality throughout the chain
Global Applied Technology Innovation Strategies
Nature of Business: Performance & Life Science Chemicals Subir Basak Exploring the viability of biobetters
• R&D and Process Development – gain in-depth guidance on advanced cloning, Merck KGaA CEO and biosuperiors
Number of Employees Annual Turnover Organisation’s Main Area of Business: Celestial Biologicals
fermentation and purification processes and their scale-up, to ensure the quality and safety of Please tick one box Please tick one box Please tick one box Rustam Modi
your biosimilars Chief Scientific Officer, Director Quality Aruna R Khare
50,000 or more More than US$40 Million Biopharma Manufacturer Packaging Supplier Principal Scientist, Incharge, Bioassay
Biotechnology Manufacturer Consultant
Assurance and Immunoassay Laboratory
10,000 - 49,999 US$30 - US$40 Million
Intas Biopharmaceuticals USV
• Manufacturing and Distribution – take advantage of cost-effective cGMP facilities and 5,000 - 9,999 US$20 - US$30 Million Innovator Pharma Manufacturer Regulator
cold- chain management for volume production and distribution of biosimilars 1,000 - 4,999 US$10 - US$20 Million Generic Pharma Manufacturer Academic Institute VK Vinayak UC Banerjee
500 - 999 Less than US$10 Million CRO Trade Association Vice President Research and Development Professor & Head Department of Pharmaceutical
Panacea Biotec Technology, Biotechnology
• Commercialisation – pricing, partnerships and outsourcing strategies to drive the early 250 - 499 CMO Media
NIPER
100 - 249 Analytical Laboratory Sanjay Singh
profitability of your biosimilars business CEO Samir Sangitrao
1 to 99 Ingredient Supplier
Gennova Biopharmaceuticals Head Regulatory Affairs
Intas Biopharmaceuticals
• Biobetters and Biosuperiors – pave the way today to reap the longer term rewards of the How to pay Bookings received less than thirty days before the conference date can only be paid by credit card Vikram Paradkar
biologics market in India Vishwanath B Malkar
Vice President Biotechnology Head Regulatory and Quality
Terms & Conditions: It may be necessary due to unforeseen Reliance Life Sciences Reliance Life Sciences
Cheque circumstances to alter the content, timing, speakers or venue. This
contract is subject to Mumbai Jurisdiction law. Vijay Kshirsagar Krishnamohan B
We have assembled an outstanding line-up of industry leading speakers including senior Fees: Conference fees include entrance to the conference Executive Vice President, General Manager Operations,
Please find enclosed a cheque for the amount of INR US$
representatives of: Merck KGaA, Intas Biopharmaceuticals, Wockhardt, Panacea Biotec, sessions, refreshments as per onsite schedule, and the conference
Corporate Quality Assurance Biotech Division
made payable to UBM India Pvt. Ltd. Please send to address above (in WAYS TO REGISTER box) papers. Fees are subject to applicable taxes as per government
Lupin Pharmaceuticals, Gennova Biopharmaceuticals, Reliance Life Sciences, USV, rules and regulations. Please note that accommodation and travel and Regulatory Affairs Lupin Pharmaceuticals
Shasun Chemicals and Drugs, Unichem Laboratories, plus many more… are not included in the conference fee. Unichem Laboratories Hareesh Parandhaman
Bank Transfer Substitutions: Once booked cancellation of delegate places Head Business Development,
Anand Kumar
can not be made, however substitution can be made at any time.
Associate Vice Biotechnology
Don’t delay! Call us today to secure your place at the only Biosimilars conference focused on the Please email details of the substitute delegate to Lupin Pharmaceuticals
Email (accounts contact) conferences@ubmindia.com at the earliest opportunity. President, Quality
opportunities and challenges of the Indian market specifically! Invoice Address (if different from above Accommodation: Orbitz are the officially appointed accom- Wockhardt plus many more...
modation agency. Orbitz have secured allocations at conveniently
Booking is easy! Just call us on +91 (022) 4046 1466, email conferences@ubmindia.com or Purchase Order No. (where applicable) located hotels to the venue at discounted event rates. These rates
are held for a limited amount of time, please book early to avoid
To pay by bank transfer please send payments to: HSBC Bank, 52/60, MG Road, Fort Mumbai, 400 001, India. Beneficiary Name: UBM India
visit www.biosimilars-india.com Pvt Ltd. Type of Account: Current. MICR No: 400039002. IFSC Code: HSBC0400002. Swift Code: HSBCINBB. Bank Code/Bank ID: 039. Branch disappointment. Call +91 (0)22 2410 2801/2/3 or
Code: 002. For INR and USD payments Account Number: 002-859882-004. Please fax a copy with delegate(s) and conference name of your email miceindia@orbit-elite.com
bank transfer to +91 (0)22 4046 1477. Please note that invoice will be sent separately. For invoice queries call: +91 (0)22 4046 1466. Data Protection: By entering your details in the fields above,
I look forward to seeing you at the event in September. you agree to allow UBM India Pvt Ltd. and companies associated
Credit Card/Debit Card with the event to contact you (by post, telephone, sms, email or
fax) regarding relevant products or services provided. If at any
Best wishes, Please debit my:
time you do not wish to receive anything from i) UBM India Pvt
Ltd. or ii) carefully selected 3rd parties, please write to Manoj Organised by Media Partners
Card No: Expiry Date:
Ambardekar, Database Manager, UBM India Pvt Ltd. Sagar Tech
Issue No (for Maestro) Valid From: Amount: Security Code: Plaza A, 119, 1st Floor, Andheri Kurla Road, Saki Naka Junction,
Andheri East, Mumbai, 400072, India. Or
Niyoti Trivedi Vyas Card Holder’s Name:
email manoj.ambardekar@ubm.com for more information.
Programme Manager Billing Address
Service Tax Registered No. AAACU8181DST001
CPhI Conferences Issuing Bank
Signature:
*I have read the cancellation policy and agree with the terms and conditions. I authorise my credit/debit card for the above payment Customer Code: Web To register - Tel +91 (022) 4046 1466, Fax +91 (022) 4046 1477, Email conferences@ubmindia.com
www.biosimilars-india.com
 biosimilars
I N D I A 2 0 1 0
biosimilars
I N D I A 2 0 1 0
biosimilars
I N D I A 2 0 1 0

Conference Day One – Thursday 30 September 2010 Conference Day two – Friday 1 October 2010
“ The global biosimilars market is expected to be worth $19.4 billion by 2014, growing at a CAGR of 89.1%
from 2009 to 2014. The early commercialisation and high absorption rate of biosimilars products made Asia

”
09:00 Registration and refreshments 14:30 Optimising your biosimilars commercialisation strategy to 09:00 Registration and refreshments 14:30 Working with complex monoclonal antibodies to deliver the dominant market in 2008 with 34.1% share of the global biosimilars product market. Markets and Markets
ensure rapid market take-up and healthy profit margins commercially viable biosimilars to the market
10:00 Opening remarks from the chair - Biosimilar development, • Overview of the similarities and differences between monoclonal and JUST SOME OF THE ATTENDEeS AT Biosimilars India 2009:
• Assessing the different commercial opportunities for biosimilars in India 10:00 Opening remarks from the chair Market With Highest Potential For Biosimilars Penetration
opportunities and challenges • Overcoming barriers to market entry and ensuring rapid take up of the non-monoclonal antibodies CIPLA GE HEALTHCARE - LIFE SCIENCES
MK Sahib, Director Biotechnology product • Increasing the yield through effective cloning and fermentation 4.5 Level of Penetration 1-5 DR REDDYS PROLONG PHARMACEUTICALS
Wockhardt R&D and Process Development
• Developing and understanding the 4P strategy for biosimilars techniques 3.5 ELDER PHARMACEUTICALS PROXY LABORATORIES
10:10 Overcoming challenges in the cloning and fermentation process • Overcoming the purification and stabilisation challenges GLAXOSMITHKLINE
Gaining Regulatory Approval • Identifying case study benchmarks for biosimilars 2.5
WALLACE PHARMACEUTICALS
Subir Basak, CEO to maximise yield and ensure the commercial viability of • Working with the structural differences in laboratories and their impact INTAS BIOPHARMACEUTICALS
VITANE PHARMACEUTICALS
10:20 Clarifying the biosimilars regulatory position in India and biosimilars on clinical development 1.5 JOHNSON & JOHNSON
Celestial Biologicals • Taking advantage of the benefits of fully humanised monoclonal UNITED LABORATORIES
identifying strategies for gaining speedy market authorisation for • Managing the technical complexities around the cloning process: .0 LUPIN PHARMACEUTICALS (BIOTECH)
new products - Instability antibodies US EU C&E Europe S America China India MERCK & CO
NCE LIFESCIENCES
• Mapping out the current biosimilars regulatory approval process and 15:10 Striking win-win international partnerships to drive the effective VK Vinayak, Vice President Research and Development AJINOMOTO
identifying gaps and bottlenecks in the framework development and commercialisation of biosimilars - Immunogenicity Source: Business Insight Survey PANACEA BIOTEC
Panacea Biotec ALPHA PHARMACY
• Understanding the regulatory requirements around: • Identifying the key criteria for selecting and securing international - Screening of clones Total World Biogenerics Market Potential PIRAMAL HEALTHCARE
AMRONCO LIFESCIENCES
- Clinical trials partnerships for biosimilars product development and commercialisation • Developing the optimal fermentation environment to ensure maximum 15:10 Developing a scaling-up process that protects product quality 6000
RELIANCE LIFE SCIENCES

in Millions of Dollars
ANALYTICAL SOLUTIONS
- Comparative analysis • Ensuring effective due diligence procedures to ensure a robust output whilst ensuring cost-efficiency 5000
SANOFI-SYNTHELAB (INDIA)
- Documentation partnership from the outset • Establishing the optimal parameters for scaling up • Establishing the appropriate parameters for fermentation kinetics to 4000
SUN PHARMACEUTICALS BC WORLD PHARM
• Establishing the correct form and volume of data required to ensure a • Evaluating the benefits and pitfalls of various partnership approaches: • Evaluating a range of low-cost, high-performance equipment to ensure optimise productivity levels 3000 IPCA LABORATORIES AWEX
timely approval process - Joint ventures the flexibility of the fermentation process • Understanding the impact of scaling up on process and product related 2000 SHASUN CHEMICALS AND DRUGS AXELLIA PHARMACEUTICALS
• Setting out realistic timelines for R&D, product development and - Strategic alliances impurities TAKEDA
commercialisation of biosimilars Gopal Dasika, Vice President, Biotechnology 1000 BIOSERVE CLINICAL RESEARCH
- Plain vanilla Unichem Laboratories • Dealing with issues related to quality and physical verification of 0 SERUM INSTITUTE OF INDIA CHIYODA CORPORATION
• Updating on how the guidelines are evolving with input from the industry equipment 2006 2007 2008 2009 2010 2011 2012
Vishwanath B Malkar, Head Regulatory and Quality • Setting up effective contracts to protect your interests whilst allowing TORRENT PHARMACEUTICALS INDOCO REMEDIES
flexibility to upgrade with ease • Ensuring compliance with sophisticated PLC standards for quality Source: Kalorama Information 2008
UNICHEM LABORATORIES
Reliance Life Sciences 10:50 Addressing downstream process challenges through advanced control and productivity
LABORATORIES RECALCINE
• Identifying the optimal partnership model to fuel high quality clinical purification techniques to meet pharmacopic requirements
USV
MACTER INTERNATIONAL
Vikram Paradkar, Vice President Biotechnology
11:00 Adapting to stringent European regulations to ensure the timely trials APOTEX RESEARCH
and successful commercialisation of products in western Hareesh Parandhaman, Head Business Development,
• Evaluating a range of downstream processes to achieve effective
purification
Reliance Life Sciences
5 Great Reasons to Attend Who Should Attend? AGILENT TECHNOLOGIES
QUALITY PHARMA PRODUCTS
SHANKU’S BIOSCIENCES
markets Biotechnology ABEXOME BIOSCIENCES
• Evaluating the key challenges of gaining biosimilars regulatory approvals • Analysing the benefits of chromatographic techniques for managing the 15:50 Afternoon refreshments SYNAPSE LABS
Lupin Pharmaceuticals This conference has been designed MATRIX LABORATORIES
in Europe bioactivity of large and complex molecules • Understand the latest WHO guidelines SVAN PHARMACARE
16:20 Achieving comparability of biosimilars to the innovator product - specifically for VPs, Directors, GMs and ALKEM LABORATORIES
• Establishing the range and level of clinical trials required to achieve 15:50 Afternoon refreshments • Assessing folding and re-folding techniques for achieving purification and how they will interwork with the Heads of: Biologics, Biotechnology, R&D, CLARIS LIFESCIENCES THOMSON REUTERS HEALTHCARE
approvals quality considerations
• Leveraging cost-effective equipment and technologies to optimise yield Indian regulatory framework Process Development, Formulations, BHARAT SERUMS & VACCINES SHRESTH PHARMA NEXUS
• Determining the depth of comparative analysis required • Considerations for selection of the reference innovator product
16:20 Developing an outsourcing model that will deliver cost-effective and ensure safety • Selecting the right analytical methods • Gain in-depth insights into the R&D and Analysis and Testing, Regulation, and Product EVONIK DEGUSSA INDIA IBIOTECH
• Understanding the documentation complexities for European approvals
and high quality biosimilars products UC Banerjee, Professor & Head Department of Pharmaceutical • Identifying an appropriate laboratory for testing - assessing all the Development from: HELVOET PHARMA BELGIUM
Partha Ghosh, Director, Service Lead, Early Stage Development, process development complexities DAEWON PHARM
Europe • Comparing the benefits of in-house versus outsourced models for R&D, Technology, Biotechnology success factors INDEUS LIFE SCIENCES EL-SHADDAI BIOLOGICALS
NIPER • Creating the right documentation including expert opinion • Optimise your biosimilars • Biopharma Manufacturers
Parexel Consulting process development and manufacturing
• Assessing the capabilities of CRAMS in India and how facilities must Narasimham Jammi, Head Biotechnology Anand Kumar, Associate Vice President, Quality commercialisation strategy and explore • Biotechnology Manufacturers
11:40 Morning refreshments develop to meet the needs of biosimilars product manufacturers Shasun Chemicals and Drugs Wockhardt best partnership and outsourcing • Generic Pharma Manufacturers
• Learning from experiences with outsourcing of biosimilars R&D, process models • Innovator Pharma Manufacturers
12:10 Understanding the latest WHO guidelines for developing and development and manufacturing in Europe 11:30 Morning refreshments Manufacturing and Distribution
commercialising biosimilars in emerging markets • Explore longer term opportunities with • Equipment Suppliers
• Identifying the key success criteria for selecting outsourcing partners 17:00 Establishing the cGMP facility requirements for cost-effective,
• Clarifying the evolving WHO guidelines for biosimilars development and
• Evaluating the economic case and balancing with the need to retain large-scale biosimilars production biobetters and biosuperiors • Ingredient & Material Suppliers
commercialisation 12:00 Identifying advanced techniques for addressing immunogenicity
control over the product development process issues in biosimilars
• Ensuring effective collaboration of the manufacturing function with R&D • Ensure cost-effective manufacturing • Analytical Laboratories
• Effectively interworking WHO guidelines with the Indian regulatory and process development
framework Speaker to be confirmed • Understanding the level of immunogenicity analysis required for and distribution strategies • CRAMS
• Delivering on the parameters as recommended by the pilot:
• Establishing timelines for implementing the combined framework regulatory approval - Designing capacity Delegates at a previous UBM conference in India
• Consulting with industry to ensure a holistic, in-depth and clear 17:00 Biobetters & biosuperiors - paving the way for lucrative longer • Assessing the value and reliability of existing test data for informing your - Initial flow filtration level

set of guidelines for implementation ease
• Balancing the need for in-depth clinical trials with cost control of the
term opportunities
• Defining biobetters and biosuperiors and the additional studies required
biosimilars product development - TMP cross flow
Feedback from delegates at our Biosimilars 2009 conference Organised by
end product • Identifying opportunities for reducing timescales on delivering robust • Embedding an efficient process for scaling up whilst protecting the CPhI Conferences
for achieving regulatory approvals stability and quality of the product is a specialist provider
Vijay Kshirsagar, Executive Vice President, Corporate Quality immunogenicity profiles “Very good speaker selection, one of the best organised conferences in India, providing a very affordable
• Assessing the IPR issues affecting biobetters and biosuperiors • Integrating flexibility into the manufacturing process to support different of content-led
Assurance and Regulatory Affairs • Reviewing experiences with commercialised biobetters and biosuperiors • Determining the key criteria for selecting highly qualified laboratories for and fruitful platform for networking” conferences and
Unichem Laboratories immunogenicity testing biological products seminars aimed at the fast growth segments of the Indian
to date • Eliminating process variations and managing the effects of deviation in Manjula Das, Chief Scientific Officer, Abexome Biosciences pharmaceutical industry. We monitor markets, identify
• Managing the costs of delivering high quality test data the most critical trends and provide timely conferences
Commercialisation of Biosimilars • Assessing the technical complexities of developing these products the most cost-efficient manner to help you assess and target new business opportunities
• Building the business case for investing in biobetters and biosuperiors Aruna R Khare, Principal Scientist, Incharge, Bioassay and Krishnamohan B, General Manager Operations, Biotech Division “Very valuable to hear from speakers with up-to-the minute information. Especially impressed with the in India. Each of our events is extensively researched with
12:50 Evaluating the biosimilars market opportunity across the Immunoassay Laboratory representatives of both the local and international markets,
semi-regulated countries and determining the pharmacopeial Steffen Denzinger, Associate Director PC-SR Global Applied Lupin Pharmaceuticals participation and questions raised” and designed specifically to bring these audiences together
Technology Performance & Life Science Chemicals USV to discuss, debate, network and create profitable new
requirements Bina Ramani, CEO, NCE LifeSciences partnerships! Backed by an extensive network of local and
• Assessing the commercial opportunities for biosimilars in semi- Merck KGaA 17:40 Understanding the cold chain management requirements for the international exhibitions, online portals and magazines,
regulated markets 12:40 Running advanced comparability studies to deliver cost-effective storage and distribution of biosimilars “Biosimilars are the new stream to be explored. Such conferences are critical to understanding the future our access to senior level decision makers across the
• Assessing the cold chain management needs of biosimilars as Pharmaceutical, Biopharma and Outsourcing industries
• Overcoming barriers to market entry and driving rapid take-up through 17:40 Roundtable Discussions - an opportunity to join in with facilitated biosimilars approach and making successful submissions” remains unrivalled!
robust and locally oriented marketing strategies group discussions around the key issues raised during the course of • Assessing the challenges of matching biosimilars to the innovator compared with other biological products
• Examining the latest innovations in dedicated cold chain and distribution Anita S Ghagare, Senior Manager Regulatory Affairs, Unichem Laboratories CPhI India and the
• Evaluating the regulatory framework and identifying effective ways of the day. Come armed with your live challenges and take away practical product in terms of quality and structural and physical characterisation co-located P-MEC and ICSE
navigating these services are the leading international
implementable solutions. • Determining the best quality testing procedure for establishing safety of
• Managing the effects of frequently changing market and regulatory • Overcoming the challenges of continuous monitoring of in-transit trade exhibitions for
the profile in pre-clinical studies pharmaceutical ingredients and allied industries. P-MEC
environments biological products is now the largest exhibition for the pharmaceutical
18:30 Close of conference day one
• Evaluating the need for and path towards harmonisation of regulatory
regimes and agency requirements across the semi-regulated markets
• Evaluating various sensitivity techniques to deal with safety and
immunogenicity issues
• Finding a cost-effective means of dealing with power cuts and other cold
chain barriers
Promote Your Business Exhibition Floor Plan machinery and equipment industry in India. ICSE is India’s
fastest growing event for the burgeoning outsourcing
and contract services sector. The BioPh trail highlights
• Understanding regulatory and pharmacopeial expectations from analytics • Understanding the level of expertise required to assess minor variations • Developing effective processes to ensure compliance with end-to-end Sponsoring or exhibiting at Biosimilars India 2010 is an excellent way to promote your companies dealing with the research and development of
and monographs cold chain culture new treatment methods made through biotechnological
• Assessing advanced technical equipment for ensuring quality and cost- business to a highly targeted group of key decision makers with a specific interest Coffee &
Lunch point processes or which are derived from or use live organisms.
• Analysing future requirements and initiatives needed for driving growth efficiency • Assessing state-of-the-art equipment for cold chain management of in biosimilars ingredients, materials, and outsourcing services. We have a range
sold
This 3-day event provides a platform for the announcement
of Indian pharma industry Sanjay Singh, CEO biosimilars of business development and marketing and sales solutions that will be tailored to
of major pharmaceutical company launches, expansion
plans and joint ventures. The successful launch of
Samir Sangitrao, Head Regulatory Affairs Rustam Modi, Chief Scientific Officer, Director Quality Assurance specifically deliver on your business objectives. To find out more about how you can Biosimilars India 2009 conference brought together the
Intas Biopharmaceuticals Gennova Biopharmaceuticals Intas Biopharmaceuticals
sold

who’s who of the pharmaceutical industry, and acted as a

make the most of your participation at this event, contact Cherwyn Martins, Sales catalyst for the exchange of expertise, technical know-how,
Manager, on +91 (022) 6612 2692 or email cherwyn.martins@ubm.com and innovations. For more information please visit:
13:30 Lunch and networking 13:20 Lunch and networking 18:20 Close of conference www.cphi-india.com
Panelists at a previous UBM conference in India

Tel +91 (022) 4046 1466 Fax +91 (022) 4046 1477 Email conferences@ubmindia.com www.biosimilars-india.com
©2010. UBM India Pvt. Ltd. This programme may change due to unforeseen circumstances. UBM India Pvt. Ltd. reserves the right to alter the venue and/or speakers.
 biosimilars
I N D I A 2 0 1 0
biosimilars
I N D I A 2 0 1 0
biosimilars
I N D I A 2 0 1 0

Conference Day One – Thursday 30 September 2010 Conference Day two – Friday 1 October 2010
“ The global biosimilars market is expected to be worth $19.4 billion by 2014, growing at a CAGR of 89.1%
from 2009 to 2014. The early commercialisation and high absorption rate of biosimilars products made Asia

”
09:00 Registration and refreshments 14:30 Optimising your biosimilars commercialisation strategy to 09:00 Registration and refreshments 14:30 Working with complex monoclonal antibodies to deliver the dominant market in 2008 with 34.1% share of the global biosimilars product market. Markets and Markets
ensure rapid market take-up and healthy profit margins commercially viable biosimilars to the market
10:00 Opening remarks from the chair - Biosimilar development, • Overview of the similarities and differences between monoclonal and JUST SOME OF THE ATTENDEeS AT Biosimilars India 2009:
• Assessing the different commercial opportunities for biosimilars in India 10:00 Opening remarks from the chair Market With Highest Potential For Biosimilars Penetration
opportunities and challenges • Overcoming barriers to market entry and ensuring rapid take up of the non-monoclonal antibodies CIPLA GE HEALTHCARE - LIFE SCIENCES
MK Sahib, Director Biotechnology product • Increasing the yield through effective cloning and fermentation 4.5 Level of Penetration 1-5 DR REDDYS PROLONG PHARMACEUTICALS
Wockhardt R&D and Process Development
• Developing and understanding the 4P strategy for biosimilars techniques 3.5 ELDER PHARMACEUTICALS PROXY LABORATORIES
10:10 Overcoming challenges in the cloning and fermentation process • Overcoming the purification and stabilisation challenges GLAXOSMITHKLINE
Gaining Regulatory Approval • Identifying case study benchmarks for biosimilars 2.5
WALLACE PHARMACEUTICALS
Subir Basak, CEO to maximise yield and ensure the commercial viability of • Working with the structural differences in laboratories and their impact INTAS BIOPHARMACEUTICALS
VITANE PHARMACEUTICALS
10:20 Clarifying the biosimilars regulatory position in India and biosimilars on clinical development 1.5 JOHNSON & JOHNSON
Celestial Biologicals • Taking advantage of the benefits of fully humanised monoclonal UNITED LABORATORIES
identifying strategies for gaining speedy market authorisation for • Managing the technical complexities around the cloning process: .0 LUPIN PHARMACEUTICALS (BIOTECH)
new products - Instability antibodies US EU C&E Europe S America China India MERCK & CO
NCE LIFESCIENCES
• Mapping out the current biosimilars regulatory approval process and 15:10 Striking win-win international partnerships to drive the effective VK Vinayak, Vice President Research and Development AJINOMOTO
identifying gaps and bottlenecks in the framework development and commercialisation of biosimilars - Immunogenicity Source: Business Insight Survey PANACEA BIOTEC
Panacea Biotec ALPHA PHARMACY
• Understanding the regulatory requirements around: • Identifying the key criteria for selecting and securing international - Screening of clones Total World Biogenerics Market Potential PIRAMAL HEALTHCARE
AMRONCO LIFESCIENCES
- Clinical trials partnerships for biosimilars product development and commercialisation • Developing the optimal fermentation environment to ensure maximum 15:10 Developing a scaling-up process that protects product quality 6000
RELIANCE LIFE SCIENCES

in Millions of Dollars
ANALYTICAL SOLUTIONS
- Comparative analysis • Ensuring effective due diligence procedures to ensure a robust output whilst ensuring cost-efficiency 5000
SANOFI-SYNTHELAB (INDIA)
- Documentation partnership from the outset • Establishing the optimal parameters for scaling up • Establishing the appropriate parameters for fermentation kinetics to 4000
SUN PHARMACEUTICALS BC WORLD PHARM
• Establishing the correct form and volume of data required to ensure a • Evaluating the benefits and pitfalls of various partnership approaches: • Evaluating a range of low-cost, high-performance equipment to ensure optimise productivity levels 3000 IPCA LABORATORIES AWEX
timely approval process - Joint ventures the flexibility of the fermentation process • Understanding the impact of scaling up on process and product related 2000 SHASUN CHEMICALS AND DRUGS AXELLIA PHARMACEUTICALS
• Setting out realistic timelines for R&D, product development and - Strategic alliances impurities TAKEDA
commercialisation of biosimilars Gopal Dasika, Vice President, Biotechnology 1000 BIOSERVE CLINICAL RESEARCH
- Plain vanilla Unichem Laboratories • Dealing with issues related to quality and physical verification of 0 SERUM INSTITUTE OF INDIA CHIYODA CORPORATION
• Updating on how the guidelines are evolving with input from the industry equipment 2006 2007 2008 2009 2010 2011 2012
Vishwanath B Malkar, Head Regulatory and Quality • Setting up effective contracts to protect your interests whilst allowing TORRENT PHARMACEUTICALS INDOCO REMEDIES
flexibility to upgrade with ease • Ensuring compliance with sophisticated PLC standards for quality Source: Kalorama Information 2008
UNICHEM LABORATORIES
Reliance Life Sciences 10:50 Addressing downstream process challenges through advanced control and productivity
LABORATORIES RECALCINE
• Identifying the optimal partnership model to fuel high quality clinical purification techniques to meet pharmacopic requirements
USV
MACTER INTERNATIONAL
Vikram Paradkar, Vice President Biotechnology
11:00 Adapting to stringent European regulations to ensure the timely trials APOTEX RESEARCH
and successful commercialisation of products in western Hareesh Parandhaman, Head Business Development,
• Evaluating a range of downstream processes to achieve effective
purification
Reliance Life Sciences
5 Great Reasons to Attend Who Should Attend? AGILENT TECHNOLOGIES
QUALITY PHARMA PRODUCTS
SHANKU’S BIOSCIENCES
markets Biotechnology ABEXOME BIOSCIENCES
• Evaluating the key challenges of gaining biosimilars regulatory approvals • Analysing the benefits of chromatographic techniques for managing the 15:50 Afternoon refreshments SYNAPSE LABS
Lupin Pharmaceuticals This conference has been designed MATRIX LABORATORIES
in Europe bioactivity of large and complex molecules • Understand the latest WHO guidelines SVAN PHARMACARE
16:20 Achieving comparability of biosimilars to the innovator product - specifically for VPs, Directors, GMs and ALKEM LABORATORIES
• Establishing the range and level of clinical trials required to achieve 15:50 Afternoon refreshments • Assessing folding and re-folding techniques for achieving purification and how they will interwork with the Heads of: Biologics, Biotechnology, R&D, CLARIS LIFESCIENCES THOMSON REUTERS HEALTHCARE
approvals quality considerations
• Leveraging cost-effective equipment and technologies to optimise yield Indian regulatory framework Process Development, Formulations, BHARAT SERUMS & VACCINES SHRESTH PHARMA NEXUS
• Determining the depth of comparative analysis required • Considerations for selection of the reference innovator product
16:20 Developing an outsourcing model that will deliver cost-effective and ensure safety • Selecting the right analytical methods • Gain in-depth insights into the R&D and Analysis and Testing, Regulation, and Product EVONIK DEGUSSA INDIA IBIOTECH
• Understanding the documentation complexities for European approvals
and high quality biosimilars products UC Banerjee, Professor & Head Department of Pharmaceutical • Identifying an appropriate laboratory for testing - assessing all the Development from: HELVOET PHARMA BELGIUM
Partha Ghosh, Director, Service Lead, Early Stage Development, process development complexities DAEWON PHARM
Europe • Comparing the benefits of in-house versus outsourced models for R&D, Technology, Biotechnology success factors INDEUS LIFE SCIENCES EL-SHADDAI BIOLOGICALS
NIPER • Creating the right documentation including expert opinion • Optimise your biosimilars • Biopharma Manufacturers
Parexel Consulting process development and manufacturing
• Assessing the capabilities of CRAMS in India and how facilities must Narasimham Jammi, Head Biotechnology Anand Kumar, Associate Vice President, Quality commercialisation strategy and explore • Biotechnology Manufacturers
11:40 Morning refreshments develop to meet the needs of biosimilars product manufacturers Shasun Chemicals and Drugs Wockhardt best partnership and outsourcing • Generic Pharma Manufacturers
• Learning from experiences with outsourcing of biosimilars R&D, process models • Innovator Pharma Manufacturers
12:10 Understanding the latest WHO guidelines for developing and development and manufacturing in Europe 11:30 Morning refreshments Manufacturing and Distribution
commercialising biosimilars in emerging markets • Explore longer term opportunities with • Equipment Suppliers
• Identifying the key success criteria for selecting outsourcing partners 17:00 Establishing the cGMP facility requirements for cost-effective,
• Clarifying the evolving WHO guidelines for biosimilars development and
• Evaluating the economic case and balancing with the need to retain large-scale biosimilars production biobetters and biosuperiors • Ingredient & Material Suppliers
commercialisation 12:00 Identifying advanced techniques for addressing immunogenicity
control over the product development process issues in biosimilars
• Ensuring effective collaboration of the manufacturing function with R&D • Ensure cost-effective manufacturing • Analytical Laboratories
• Effectively interworking WHO guidelines with the Indian regulatory and process development
framework Speaker to be confirmed • Understanding the level of immunogenicity analysis required for and distribution strategies • CRAMS
• Delivering on the parameters as recommended by the pilot:
• Establishing timelines for implementing the combined framework regulatory approval - Designing capacity Delegates at a previous UBM conference in India
• Consulting with industry to ensure a holistic, in-depth and clear 17:00 Biobetters & biosuperiors - paving the way for lucrative longer • Assessing the value and reliability of existing test data for informing your - Initial flow filtration level

set of guidelines for implementation ease
• Balancing the need for in-depth clinical trials with cost control of the
term opportunities
• Defining biobetters and biosuperiors and the additional studies required
biosimilars product development - TMP cross flow
Feedback from delegates at our Biosimilars 2009 conference Organised by
end product • Identifying opportunities for reducing timescales on delivering robust • Embedding an efficient process for scaling up whilst protecting the CPhI Conferences
for achieving regulatory approvals stability and quality of the product is a specialist provider
Vijay Kshirsagar, Executive Vice President, Corporate Quality immunogenicity profiles “Very good speaker selection, one of the best organised conferences in India, providing a very affordable
• Assessing the IPR issues affecting biobetters and biosuperiors • Integrating flexibility into the manufacturing process to support different of content-led
Assurance and Regulatory Affairs • Reviewing experiences with commercialised biobetters and biosuperiors • Determining the key criteria for selecting highly qualified laboratories for and fruitful platform for networking” conferences and
Unichem Laboratories immunogenicity testing biological products seminars aimed at the fast growth segments of the Indian
to date • Eliminating process variations and managing the effects of deviation in Manjula Das, Chief Scientific Officer, Abexome Biosciences pharmaceutical industry. We monitor markets, identify
• Managing the costs of delivering high quality test data the most critical trends and provide timely conferences
Commercialisation of Biosimilars • Assessing the technical complexities of developing these products the most cost-efficient manner to help you assess and target new business opportunities
• Building the business case for investing in biobetters and biosuperiors Aruna R Khare, Principal Scientist, Incharge, Bioassay and Krishnamohan B, General Manager Operations, Biotech Division “Very valuable to hear from speakers with up-to-the minute information. Especially impressed with the in India. Each of our events is extensively researched with
12:50 Evaluating the biosimilars market opportunity across the Immunoassay Laboratory representatives of both the local and international markets,
semi-regulated countries and determining the pharmacopeial Steffen Denzinger, Associate Director PC-SR Global Applied Lupin Pharmaceuticals participation and questions raised” and designed specifically to bring these audiences together
Technology Performance & Life Science Chemicals USV to discuss, debate, network and create profitable new
requirements Bina Ramani, CEO, NCE LifeSciences partnerships! Backed by an extensive network of local and
• Assessing the commercial opportunities for biosimilars in semi- Merck KGaA 17:40 Understanding the cold chain management requirements for the international exhibitions, online portals and magazines,
regulated markets 12:40 Running advanced comparability studies to deliver cost-effective storage and distribution of biosimilars “Biosimilars are the new stream to be explored. Such conferences are critical to understanding the future our access to senior level decision makers across the
• Assessing the cold chain management needs of biosimilars as Pharmaceutical, Biopharma and Outsourcing industries
• Overcoming barriers to market entry and driving rapid take-up through 17:40 Roundtable Discussions - an opportunity to join in with facilitated biosimilars approach and making successful submissions” remains unrivalled!
robust and locally oriented marketing strategies group discussions around the key issues raised during the course of • Assessing the challenges of matching biosimilars to the innovator compared with other biological products
• Examining the latest innovations in dedicated cold chain and distribution Anita S Ghagare, Senior Manager Regulatory Affairs, Unichem Laboratories CPhI India and the
• Evaluating the regulatory framework and identifying effective ways of the day. Come armed with your live challenges and take away practical product in terms of quality and structural and physical characterisation co-located P-MEC and ICSE
navigating these services are the leading international
implementable solutions. • Determining the best quality testing procedure for establishing safety of
• Managing the effects of frequently changing market and regulatory • Overcoming the challenges of continuous monitoring of in-transit trade exhibitions for
the profile in pre-clinical studies pharmaceutical ingredients and allied industries. P-MEC
environments biological products is now the largest exhibition for the pharmaceutical
18:30 Close of conference day one
• Evaluating the need for and path towards harmonisation of regulatory
regimes and agency requirements across the semi-regulated markets
• Evaluating various sensitivity techniques to deal with safety and
immunogenicity issues
• Finding a cost-effective means of dealing with power cuts and other cold
chain barriers
Promote Your Business Exhibition Floor Plan machinery and equipment industry in India. ICSE is India’s
fastest growing event for the burgeoning outsourcing
and contract services sector. The BioPh trail highlights
• Understanding regulatory and pharmacopeial expectations from analytics • Understanding the level of expertise required to assess minor variations • Developing effective processes to ensure compliance with end-to-end Sponsoring or exhibiting at Biosimilars India 2010 is an excellent way to promote your companies dealing with the research and development of
and monographs cold chain culture new treatment methods made through biotechnological
• Assessing advanced technical equipment for ensuring quality and cost- business to a highly targeted group of key decision makers with a specific interest Coffee &
Lunch point processes or which are derived from or use live organisms.
• Analysing future requirements and initiatives needed for driving growth efficiency • Assessing state-of-the-art equipment for cold chain management of in biosimilars ingredients, materials, and outsourcing services. We have a range
sold
This 3-day event provides a platform for the announcement
of Indian pharma industry Sanjay Singh, CEO biosimilars of business development and marketing and sales solutions that will be tailored to
of major pharmaceutical company launches, expansion
plans and joint ventures. The successful launch of
Samir Sangitrao, Head Regulatory Affairs Rustam Modi, Chief Scientific Officer, Director Quality Assurance specifically deliver on your business objectives. To find out more about how you can Biosimilars India 2009 conference brought together the
Intas Biopharmaceuticals Gennova Biopharmaceuticals Intas Biopharmaceuticals
sold

who’s who of the pharmaceutical industry, and acted as a

make the most of your participation at this event, contact Cherwyn Martins, Sales catalyst for the exchange of expertise, technical know-how,
Manager, on +91 (022) 6612 2692 or email cherwyn.martins@ubm.com and innovations. For more information please visit:
13:30 Lunch and networking 13:20 Lunch and networking 18:20 Close of conference www.cphi-india.com
Panelists at a previous UBM conference in India

Tel +91 (022) 4046 1466 Fax +91 (022) 4046 1477 Email conferences@ubmindia.com www.biosimilars-india.com
©2010. UBM India Pvt. Ltd. This programme may change due to unforeseen circumstances. UBM India Pvt. Ltd. reserves the right to alter the venue and/or speakers.
 biosimilars
I N D I A 2 0 1 0
biosimilars
I N D I A 2 0 1 0
biosimilars
I N D I A 2 0 1 0

Conference Day One – Thursday 30 September 2010 Conference Day two – Friday 1 October 2010
“ The global biosimilars market is expected to be worth $19.4 billion by 2014, growing at a CAGR of 89.1%
from 2009 to 2014. The early commercialisation and high absorption rate of biosimilars products made Asia

”
09:00 Registration and refreshments 14:30 Optimising your biosimilars commercialisation strategy to 09:00 Registration and refreshments 14:30 Working with complex monoclonal antibodies to deliver the dominant market in 2008 with 34.1% share of the global biosimilars product market. Markets and Markets
ensure rapid market take-up and healthy profit margins commercially viable biosimilars to the market
10:00 Opening remarks from the chair - Biosimilar development, • Overview of the similarities and differences between monoclonal and JUST SOME OF THE ATTENDEeS AT Biosimilars India 2009:
• Assessing the different commercial opportunities for biosimilars in India 10:00 Opening remarks from the chair Market With Highest Potential For Biosimilars Penetration
opportunities and challenges • Overcoming barriers to market entry and ensuring rapid take up of the non-monoclonal antibodies CIPLA GE HEALTHCARE - LIFE SCIENCES
MK Sahib, Director Biotechnology product • Increasing the yield through effective cloning and fermentation 4.5 Level of Penetration 1-5 DR REDDYS PROLONG PHARMACEUTICALS
Wockhardt R&D and Process Development
• Developing and understanding the 4P strategy for biosimilars techniques 3.5 ELDER PHARMACEUTICALS PROXY LABORATORIES
10:10 Overcoming challenges in the cloning and fermentation process • Overcoming the purification and stabilisation challenges GLAXOSMITHKLINE
Gaining Regulatory Approval • Identifying case study benchmarks for biosimilars 2.5
WALLACE PHARMACEUTICALS
Subir Basak, CEO to maximise yield and ensure the commercial viability of • Working with the structural differences in laboratories and their impact INTAS BIOPHARMACEUTICALS
VITANE PHARMACEUTICALS
10:20 Clarifying the biosimilars regulatory position in India and biosimilars on clinical development 1.5 JOHNSON & JOHNSON
Celestial Biologicals • Taking advantage of the benefits of fully humanised monoclonal UNITED LABORATORIES
identifying strategies for gaining speedy market authorisation for • Managing the technical complexities around the cloning process: .0 LUPIN PHARMACEUTICALS (BIOTECH)
new products - Instability antibodies US EU C&E Europe S America China India MERCK & CO
NCE LIFESCIENCES
• Mapping out the current biosimilars regulatory approval process and 15:10 Striking win-win international partnerships to drive the effective VK Vinayak, Vice President Research and Development AJINOMOTO
identifying gaps and bottlenecks in the framework development and commercialisation of biosimilars - Immunogenicity Source: Business Insight Survey PANACEA BIOTEC
Panacea Biotec ALPHA PHARMACY
• Understanding the regulatory requirements around: • Identifying the key criteria for selecting and securing international - Screening of clones Total World Biogenerics Market Potential PIRAMAL HEALTHCARE
AMRONCO LIFESCIENCES
- Clinical trials partnerships for biosimilars product development and commercialisation • Developing the optimal fermentation environment to ensure maximum 15:10 Developing a scaling-up process that protects product quality 6000
RELIANCE LIFE SCIENCES

in Millions of Dollars
ANALYTICAL SOLUTIONS
- Comparative analysis • Ensuring effective due diligence procedures to ensure a robust output whilst ensuring cost-efficiency 5000
SANOFI-SYNTHELAB (INDIA)
- Documentation partnership from the outset • Establishing the optimal parameters for scaling up • Establishing the appropriate parameters for fermentation kinetics to 4000
SUN PHARMACEUTICALS BC WORLD PHARM
• Establishing the correct form and volume of data required to ensure a • Evaluating the benefits and pitfalls of various partnership approaches: • Evaluating a range of low-cost, high-performance equipment to ensure optimise productivity levels 3000 IPCA LABORATORIES AWEX
timely approval process - Joint ventures the flexibility of the fermentation process • Understanding the impact of scaling up on process and product related 2000 SHASUN CHEMICALS AND DRUGS AXELLIA PHARMACEUTICALS
• Setting out realistic timelines for R&D, product development and - Strategic alliances impurities TAKEDA
commercialisation of biosimilars Gopal Dasika, Vice President, Biotechnology 1000 BIOSERVE CLINICAL RESEARCH
- Plain vanilla Unichem Laboratories • Dealing with issues related to quality and physical verification of 0 SERUM INSTITUTE OF INDIA CHIYODA CORPORATION
• Updating on how the guidelines are evolving with input from the industry equipment 2006 2007 2008 2009 2010 2011 2012
Vishwanath B Malkar, Head Regulatory and Quality • Setting up effective contracts to protect your interests whilst allowing TORRENT PHARMACEUTICALS INDOCO REMEDIES
flexibility to upgrade with ease • Ensuring compliance with sophisticated PLC standards for quality Source: Kalorama Information 2008
UNICHEM LABORATORIES
Reliance Life Sciences 10:50 Addressing downstream process challenges through advanced control and productivity
LABORATORIES RECALCINE
• Identifying the optimal partnership model to fuel high quality clinical purification techniques to meet pharmacopic requirements
USV
MACTER INTERNATIONAL
Vikram Paradkar, Vice President Biotechnology
11:00 Adapting to stringent European regulations to ensure the timely trials APOTEX RESEARCH
and successful commercialisation of products in western Hareesh Parandhaman, Head Business Development,
• Evaluating a range of downstream processes to achieve effective
purification
Reliance Life Sciences
5 Great Reasons to Attend Who Should Attend? AGILENT TECHNOLOGIES
QUALITY PHARMA PRODUCTS
SHANKU’S BIOSCIENCES
markets Biotechnology ABEXOME BIOSCIENCES
• Evaluating the key challenges of gaining biosimilars regulatory approvals • Analysing the benefits of chromatographic techniques for managing the 15:50 Afternoon refreshments SYNAPSE LABS
Lupin Pharmaceuticals This conference has been designed MATRIX LABORATORIES
in Europe bioactivity of large and complex molecules • Understand the latest WHO guidelines SVAN PHARMACARE
16:20 Achieving comparability of biosimilars to the innovator product - specifically for VPs, Directors, GMs and ALKEM LABORATORIES
• Establishing the range and level of clinical trials required to achieve 15:50 Afternoon refreshments • Assessing folding and re-folding techniques for achieving purification and how they will interwork with the Heads of: Biologics, Biotechnology, R&D, CLARIS LIFESCIENCES THOMSON REUTERS HEALTHCARE
approvals quality considerations
• Leveraging cost-effective equipment and technologies to optimise yield Indian regulatory framework Process Development, Formulations, BHARAT SERUMS & VACCINES SHRESTH PHARMA NEXUS
• Determining the depth of comparative analysis required • Considerations for selection of the reference innovator product
16:20 Developing an outsourcing model that will deliver cost-effective and ensure safety • Selecting the right analytical methods • Gain in-depth insights into the R&D and Analysis and Testing, Regulation, and Product EVONIK DEGUSSA INDIA IBIOTECH
• Understanding the documentation complexities for European approvals
and high quality biosimilars products UC Banerjee, Professor & Head Department of Pharmaceutical • Identifying an appropriate laboratory for testing - assessing all the Development from: HELVOET PHARMA BELGIUM
Partha Ghosh, Director, Service Lead, Early Stage Development, process development complexities DAEWON PHARM
Europe • Comparing the benefits of in-house versus outsourced models for R&D, Technology, Biotechnology success factors INDEUS LIFE SCIENCES EL-SHADDAI BIOLOGICALS
NIPER • Creating the right documentation including expert opinion • Optimise your biosimilars • Biopharma Manufacturers
Parexel Consulting process development and manufacturing
• Assessing the capabilities of CRAMS in India and how facilities must Narasimham Jammi, Head Biotechnology Anand Kumar, Associate Vice President, Quality commercialisation strategy and explore • Biotechnology Manufacturers
11:40 Morning refreshments develop to meet the needs of biosimilars product manufacturers Shasun Chemicals and Drugs Wockhardt best partnership and outsourcing • Generic Pharma Manufacturers
• Learning from experiences with outsourcing of biosimilars R&D, process models • Innovator Pharma Manufacturers
12:10 Understanding the latest WHO guidelines for developing and development and manufacturing in Europe 11:30 Morning refreshments Manufacturing and Distribution
commercialising biosimilars in emerging markets • Explore longer term opportunities with • Equipment Suppliers
• Identifying the key success criteria for selecting outsourcing partners 17:00 Establishing the cGMP facility requirements for cost-effective,
• Clarifying the evolving WHO guidelines for biosimilars development and
• Evaluating the economic case and balancing with the need to retain large-scale biosimilars production biobetters and biosuperiors • Ingredient & Material Suppliers
commercialisation 12:00 Identifying advanced techniques for addressing immunogenicity
control over the product development process issues in biosimilars
• Ensuring effective collaboration of the manufacturing function with R&D • Ensure cost-effective manufacturing • Analytical Laboratories
• Effectively interworking WHO guidelines with the Indian regulatory and process development
framework Speaker to be confirmed • Understanding the level of immunogenicity analysis required for and distribution strategies • CRAMS
• Delivering on the parameters as recommended by the pilot:
• Establishing timelines for implementing the combined framework regulatory approval - Designing capacity Delegates at a previous UBM conference in India
• Consulting with industry to ensure a holistic, in-depth and clear 17:00 Biobetters & biosuperiors - paving the way for lucrative longer • Assessing the value and reliability of existing test data for informing your - Initial flow filtration level

set of guidelines for implementation ease
• Balancing the need for in-depth clinical trials with cost control of the
term opportunities
• Defining biobetters and biosuperiors and the additional studies required
biosimilars product development - TMP cross flow
Feedback from delegates at our Biosimilars 2009 conference Organised by
end product • Identifying opportunities for reducing timescales on delivering robust • Embedding an efficient process for scaling up whilst protecting the CPhI Conferences
for achieving regulatory approvals stability and quality of the product is a specialist provider
Vijay Kshirsagar, Executive Vice President, Corporate Quality immunogenicity profiles “Very good speaker selection, one of the best organised conferences in India, providing a very affordable
• Assessing the IPR issues affecting biobetters and biosuperiors • Integrating flexibility into the manufacturing process to support different of content-led
Assurance and Regulatory Affairs • Reviewing experiences with commercialised biobetters and biosuperiors • Determining the key criteria for selecting highly qualified laboratories for and fruitful platform for networking” conferences and
Unichem Laboratories immunogenicity testing biological products seminars aimed at the fast growth segments of the Indian
to date • Eliminating process variations and managing the effects of deviation in Manjula Das, Chief Scientific Officer, Abexome Biosciences pharmaceutical industry. We monitor markets, identify
• Managing the costs of delivering high quality test data the most critical trends and provide timely conferences
Commercialisation of Biosimilars • Assessing the technical complexities of developing these products the most cost-efficient manner to help you assess and target new business opportunities
• Building the business case for investing in biobetters and biosuperiors Aruna R Khare, Principal Scientist, Incharge, Bioassay and Krishnamohan B, General Manager Operations, Biotech Division “Very valuable to hear from speakers with up-to-the minute information. Especially impressed with the in India. Each of our events is extensively researched with
12:50 Evaluating the biosimilars market opportunity across the Immunoassay Laboratory representatives of both the local and international markets,
semi-regulated countries and determining the pharmacopeial Steffen Denzinger, Associate Director PC-SR Global Applied Lupin Pharmaceuticals participation and questions raised” and designed specifically to bring these audiences together
Technology Performance & Life Science Chemicals USV to discuss, debate, network and create profitable new
requirements Bina Ramani, CEO, NCE LifeSciences partnerships! Backed by an extensive network of local and
• Assessing the commercial opportunities for biosimilars in semi- Merck KGaA 17:40 Understanding the cold chain management requirements for the international exhibitions, online portals and magazines,
regulated markets 12:40 Running advanced comparability studies to deliver cost-effective storage and distribution of biosimilars “Biosimilars are the new stream to be explored. Such conferences are critical to understanding the future our access to senior level decision makers across the
• Assessing the cold chain management needs of biosimilars as Pharmaceutical, Biopharma and Outsourcing industries
• Overcoming barriers to market entry and driving rapid take-up through 17:40 Roundtable Discussions - an opportunity to join in with facilitated biosimilars approach and making successful submissions” remains unrivalled!
robust and locally oriented marketing strategies group discussions around the key issues raised during the course of • Assessing the challenges of matching biosimilars to the innovator compared with other biological products
• Examining the latest innovations in dedicated cold chain and distribution Anita S Ghagare, Senior Manager Regulatory Affairs, Unichem Laboratories CPhI India and the
• Evaluating the regulatory framework and identifying effective ways of the day. Come armed with your live challenges and take away practical product in terms of quality and structural and physical characterisation co-located P-MEC and ICSE
navigating these services are the leading international
implementable solutions. • Determining the best quality testing procedure for establishing safety of
• Managing the effects of frequently changing market and regulatory • Overcoming the challenges of continuous monitoring of in-transit trade exhibitions for
the profile in pre-clinical studies pharmaceutical ingredients and allied industries. P-MEC
environments biological products is now the largest exhibition for the pharmaceutical
18:30 Close of conference day one
• Evaluating the need for and path towards harmonisation of regulatory
regimes and agency requirements across the semi-regulated markets
• Evaluating various sensitivity techniques to deal with safety and
immunogenicity issues
• Finding a cost-effective means of dealing with power cuts and other cold
chain barriers
Promote Your Business Exhibition Floor Plan machinery and equipment industry in India. ICSE is India’s
fastest growing event for the burgeoning outsourcing
and contract services sector. The BioPh trail highlights
• Understanding regulatory and pharmacopeial expectations from analytics • Understanding the level of expertise required to assess minor variations • Developing effective processes to ensure compliance with end-to-end Sponsoring or exhibiting at Biosimilars India 2010 is an excellent way to promote your companies dealing with the research and development of
and monographs cold chain culture new treatment methods made through biotechnological
• Assessing advanced technical equipment for ensuring quality and cost- business to a highly targeted group of key decision makers with a specific interest Coffee &
Lunch point processes or which are derived from or use live organisms.
• Analysing future requirements and initiatives needed for driving growth efficiency • Assessing state-of-the-art equipment for cold chain management of in biosimilars ingredients, materials, and outsourcing services. We have a range
sold
This 3-day event provides a platform for the announcement
of Indian pharma industry Sanjay Singh, CEO biosimilars of business development and marketing and sales solutions that will be tailored to
of major pharmaceutical company launches, expansion
plans and joint ventures. The successful launch of
Samir Sangitrao, Head Regulatory Affairs Rustam Modi, Chief Scientific Officer, Director Quality Assurance specifically deliver on your business objectives. To find out more about how you can Biosimilars India 2009 conference brought together the
Intas Biopharmaceuticals Gennova Biopharmaceuticals Intas Biopharmaceuticals
sold

who’s who of the pharmaceutical industry, and acted as a

make the most of your participation at this event, contact Cherwyn Martins, Sales catalyst for the exchange of expertise, technical know-how,
Manager, on +91 (022) 6612 2692 or email cherwyn.martins@ubm.com and innovations. For more information please visit:
13:30 Lunch and networking 13:20 Lunch and networking 18:20 Close of conference www.cphi-india.com
Panelists at a previous UBM conference in India

Tel +91 (022) 4046 1466 Fax +91 (022) 4046 1477 Email conferences@ubmindia.com www.biosimilars-india.com
©2010. UBM India Pvt. Ltd. This programme may change due to unforeseen circumstances. UBM India Pvt. Ltd. reserves the right to alter the venue and/or speakers.
 biosimilars
I N D I A 2 0 1 0
Organised by:
Biogenerics Follow-on-Biologics Biobetters Biosuperiors
Early Bird Discounts!
Book before 30 July 2010

biosimilars
I N D I A 2 0 1 0 Ways to Register
Save INR.10,000 / US$200
Book before 3 September 2010
Save INR.5,000 / US$100

biosimilars
30 September – 1 October 2010 Online: www.biosimilars-india.com
“The ‘Made-in-India’ biosimilars market (domestic plus Le Royal Méridien Mumbai
Tel +91 (022) 4046 1466
export) was worth around $200 million in 2008, and is Sahar Airport Road, Andheri (East)
Mumbai 400 099, India Fax +91 (022) 4046 1477
expected to more than double to reach around Tel +91 (022) 2838 0000
$580 million by 2012” (Biospectrum) Early Early Bird!!
Book and pay by Friday 30 July 2010
Please
register
Indian Delegate @ INR30,000 +10.3% Service Tax = INR33,090
International Delegate @ US$1,195 +10.3% Service Tax = US$1,318.09
Email conferences@ubmindia.com

Post Conference Department,

Early Bird!
Book and pay by Friday 3 September 2010
Please
register
Indian Delegate @ INR35,000 +10.3% Service Tax = INR38,605
International Delegate @ US$1,295 +10.3% Service Tax = US$1,428.39


UBM India Pvt Ltd, Sagar Tech Plaza A, 
119, 1st Floor, Andheri Kurla Road,
I N D I A 2 0 1 0
Standard Rate Please Indian Delegate @ INR40,000 +10.3% Service Tax = INR44,120 Saki Naka Junction, Andheri East,

Dear Colleague,
register International Delegate @ US$1,395 +10.3% Service Tax = US$1,538.69 Mumbai, 400072, India.
Two-Day Strategic Conference Gain In-Depth
Delegate Details (for ease, please attach your business card ) - Please photocopy for additional bookings Guidance on:
CPhI Conferences is delighted to announce its 2nd Annual Biosimilars India 2010 conference.
Delegate Contact Details- PLEASE COMPLETE IN BLOCK CAPITALS
30 September – 1 October 2010 Regulation
Understanding the impact of
Building on the success of our 2009 conference, we bring you a revised and refreshed agenda
that deep dives into the most timely R&D, manufacturing and regulatory challenges facing the
Le Royal Méridien Mumbai, India WHO guidelines in respect to Indian and European
Title: First Name: Surname: regulatory frameworks
biosimilars industry today! Company Name:
Commercialisation
Evaluating the market opportunities, international
There is no denying that the global biosimilars opportunity for Indian manufacturers and allied Job Title: Department: partnerships and profitable outsourcing models
Research and Development
industries is enormous. However, to take full advantage of the rewards that await, you must be fully Address: Outstanding Overcoming the cloning, fermentation and purification
equipped and aligned to tackle the technical, commercial and regulatory challenges today. Tel: Fax: Email: Contributions from: complexities to maximise yield and commercial viability
By providing your email address you consent to being contacted by email for direct marketing purposes by UBM India Pvt. Ltd.
MK Sahib Gopal Dasika Manufacturing
Attend this intensive two-day strategic conference and prepare to take your biosimilars strategy to *I have read and agree with the terms and conditions.
Vice President, Biotechnology Achieving effective collaboration of R&D, process
Director Biotechnology
the next level. Just some of the issues that will be tackled at this conference include: Signature: Wockhardt Unichem Laboratories development and manufacturing functions
Line Manager: Job Title: Narasimham Jammi Cold Chain Management
• Regulatory Developments – understand the impact of local and international regulatory Steffen Denzinger Leveraging the latest cold chain distribution
Associate Director PC-SR Head Biotechnology
scenarios and the implications for your biosimilars strategy Secretary/PA: Tel: Shasun Chemicals and Drugs systems to ensure quality throughout the chain
Global Applied Technology Innovation Strategies
Nature of Business: Performance & Life Science Chemicals Subir Basak Exploring the viability of biobetters
• R&D and Process Development – gain in-depth guidance on advanced cloning, Merck KGaA CEO and biosuperiors
Number of Employees Annual Turnover Organisation’s Main Area of Business: Celestial Biologicals
fermentation and purification processes and their scale-up, to ensure the quality and safety of Please tick one box Please tick one box Please tick one box Rustam Modi
your biosimilars Chief Scientific Officer, Director Quality Aruna R Khare
50,000 or more More than US$40 Million Biopharma Manufacturer Packaging Supplier Principal Scientist, Incharge, Bioassay
Biotechnology Manufacturer Consultant
Assurance and Immunoassay Laboratory
10,000 - 49,999 US$30 - US$40 Million
Intas Biopharmaceuticals USV
• Manufacturing and Distribution – take advantage of cost-effective cGMP facilities and 5,000 - 9,999 US$20 - US$30 Million Innovator Pharma Manufacturer Regulator
cold- chain management for volume production and distribution of biosimilars 1,000 - 4,999 US$10 - US$20 Million Generic Pharma Manufacturer Academic Institute VK Vinayak UC Banerjee
500 - 999 Less than US$10 Million CRO Trade Association Vice President Research and Development Professor & Head Department of Pharmaceutical
Panacea Biotec Technology, Biotechnology
• Commercialisation – pricing, partnerships and outsourcing strategies to drive the early 250 - 499 CMO Media
NIPER
100 - 249 Analytical Laboratory Sanjay Singh
profitability of your biosimilars business CEO Samir Sangitrao
1 to 99 Ingredient Supplier
Gennova Biopharmaceuticals Head Regulatory Affairs
Intas Biopharmaceuticals
• Biobetters and Biosuperiors – pave the way today to reap the longer term rewards of the How to pay Bookings received less than thirty days before the conference date can only be paid by credit card Vikram Paradkar
biologics market in India Vishwanath B Malkar
Vice President Biotechnology Head Regulatory and Quality
Terms & Conditions: It may be necessary due to unforeseen Reliance Life Sciences Reliance Life Sciences
Cheque circumstances to alter the content, timing, speakers or venue. This
contract is subject to Mumbai Jurisdiction law. Vijay Kshirsagar Krishnamohan B
We have assembled an outstanding line-up of industry leading speakers including senior Fees: Conference fees include entrance to the conference Executive Vice President, General Manager Operations,
Please find enclosed a cheque for the amount of INR US$
representatives of: Merck KGaA, Intas Biopharmaceuticals, Wockhardt, Panacea Biotec, sessions, refreshments as per onsite schedule, and the conference
Corporate Quality Assurance Biotech Division
made payable to UBM India Pvt. Ltd. Please send to address above (in WAYS TO REGISTER box) papers. Fees are subject to applicable taxes as per government
Lupin Pharmaceuticals, Gennova Biopharmaceuticals, Reliance Life Sciences, USV, rules and regulations. Please note that accommodation and travel and Regulatory Affairs Lupin Pharmaceuticals
Shasun Chemicals and Drugs, Unichem Laboratories, plus many more… are not included in the conference fee. Unichem Laboratories Hareesh Parandhaman
Bank Transfer Substitutions: Once booked cancellation of delegate places Head Business Development,
Anand Kumar
can not be made, however substitution can be made at any time.
Associate Vice Biotechnology
Don’t delay! Call us today to secure your place at the only Biosimilars conference focused on the Please email details of the substitute delegate to Lupin Pharmaceuticals
Email (accounts contact) conferences@ubmindia.com at the earliest opportunity. President, Quality
opportunities and challenges of the Indian market specifically! Invoice Address (if different from above Accommodation: Orbitz are the officially appointed accom- Wockhardt plus many more...
modation agency. Orbitz have secured allocations at conveniently
Booking is easy! Just call us on +91 (022) 4046 1466, email conferences@ubmindia.com or Purchase Order No. (where applicable) located hotels to the venue at discounted event rates. These rates
are held for a limited amount of time, please book early to avoid
To pay by bank transfer please send payments to: HSBC Bank, 52/60, MG Road, Fort Mumbai, 400 001, India. Beneficiary Name: UBM India
visit www.biosimilars-india.com Pvt Ltd. Type of Account: Current. MICR No: 400039002. IFSC Code: HSBC0400002. Swift Code: HSBCINBB. Bank Code/Bank ID: 039. Branch disappointment. Call +91 (0)22 2410 2801/2/3 or
Code: 002. For INR and USD payments Account Number: 002-859882-004. Please fax a copy with delegate(s) and conference name of your email miceindia@orbit-elite.com
bank transfer to +91 (0)22 4046 1477. Please note that invoice will be sent separately. For invoice queries call: +91 (0)22 4046 1466. Data Protection: By entering your details in the fields above,
I look forward to seeing you at the event in September. you agree to allow UBM India Pvt Ltd. and companies associated
Credit Card/Debit Card with the event to contact you (by post, telephone, sms, email or
fax) regarding relevant products or services provided. If at any
Best wishes, Please debit my:
time you do not wish to receive anything from i) UBM India Pvt
Ltd. or ii) carefully selected 3rd parties, please write to Manoj Organised by Media Partners
Card No: Expiry Date:
Ambardekar, Database Manager, UBM India Pvt Ltd. Sagar Tech
Issue No (for Maestro) Valid From: Amount: Security Code: Plaza A, 119, 1st Floor, Andheri Kurla Road, Saki Naka Junction,
Andheri East, Mumbai, 400072, India. Or
Niyoti Trivedi Vyas Card Holder’s Name:
email manoj.ambardekar@ubm.com for more information.
Programme Manager Billing Address
Service Tax Registered No. AAACU8181DST001
CPhI Conferences Issuing Bank
Signature:
*I have read the cancellation policy and agree with the terms and conditions. I authorise my credit/debit card for the above payment Customer Code: Web To register - Tel +91 (022) 4046 1466, Fax +91 (022) 4046 1477, Email conferences@ubmindia.com
www.biosimilars-india.com
 biosimilars
I N D I A 2 0 1 0
Organised by:
Biogenerics Follow-on-Biologics Biobetters Biosuperiors
Early Bird Discounts!
Book before 30 July 2010

biosimilars
I N D I A 2 0 1 0 Ways to Register
Save INR.10,000 / US$200
Book before 3 September 2010
Save INR.5,000 / US$100

biosimilars
30 September – 1 October 2010 Online: www.biosimilars-india.com
“The ‘Made-in-India’ biosimilars market (domestic plus Le Royal Méridien Mumbai
Tel +91 (022) 4046 1466
export) was worth around $200 million in 2008, and is Sahar Airport Road, Andheri (East)
Mumbai 400 099, India Fax +91 (022) 4046 1477
expected to more than double to reach around Tel +91 (022) 2838 0000
$580 million by 2012” (Biospectrum) Early Early Bird!!
Book and pay by Friday 30 July 2010
Please
register
Indian Delegate @ INR30,000 +10.3% Service Tax = INR33,090
International Delegate @ US$1,195 +10.3% Service Tax = US$1,318.09
Email conferences@ubmindia.com

Post Conference Department,

Early Bird!
Book and pay by Friday 3 September 2010
Please
register
Indian Delegate @ INR35,000 +10.3% Service Tax = INR38,605
International Delegate @ US$1,295 +10.3% Service Tax = US$1,428.39


UBM India Pvt Ltd, Sagar Tech Plaza A, 
119, 1st Floor, Andheri Kurla Road,
I N D I A 2 0 1 0
Standard Rate Please Indian Delegate @ INR40,000 +10.3% Service Tax = INR44,120 Saki Naka Junction, Andheri East,

Dear Colleague,
register International Delegate @ US$1,395 +10.3% Service Tax = US$1,538.69 Mumbai, 400072, India.
Two-Day Strategic Conference Gain In-Depth
Delegate Details (for ease, please attach your business card ) - Please photocopy for additional bookings Guidance on:
CPhI Conferences is delighted to announce its 2nd Annual Biosimilars India 2010 conference.
Delegate Contact Details- PLEASE COMPLETE IN BLOCK CAPITALS
30 September – 1 October 2010 Regulation
Understanding the impact of
Building on the success of our 2009 conference, we bring you a revised and refreshed agenda
that deep dives into the most timely R&D, manufacturing and regulatory challenges facing the
Le Royal Méridien Mumbai, India WHO guidelines in respect to Indian and European
Title: First Name: Surname: regulatory frameworks
biosimilars industry today! Company Name:
Commercialisation
Evaluating the market opportunities, international
There is no denying that the global biosimilars opportunity for Indian manufacturers and allied Job Title: Department: partnerships and profitable outsourcing models
Research and Development
industries is enormous. However, to take full advantage of the rewards that await, you must be fully Address: Outstanding Overcoming the cloning, fermentation and purification
equipped and aligned to tackle the technical, commercial and regulatory challenges today. Tel: Fax: Email: Contributions from: complexities to maximise yield and commercial viability
By providing your email address you consent to being contacted by email for direct marketing purposes by UBM India Pvt. Ltd.
MK Sahib Gopal Dasika Manufacturing
Attend this intensive two-day strategic conference and prepare to take your biosimilars strategy to *I have read and agree with the terms and conditions.
Vice President, Biotechnology Achieving effective collaboration of R&D, process
Director Biotechnology
the next level. Just some of the issues that will be tackled at this conference include: Signature: Wockhardt Unichem Laboratories development and manufacturing functions
Line Manager: Job Title: Narasimham Jammi Cold Chain Management
• Regulatory Developments – understand the impact of local and international regulatory Steffen Denzinger Leveraging the latest cold chain distribution
Associate Director PC-SR Head Biotechnology
scenarios and the implications for your biosimilars strategy Secretary/PA: Tel: Shasun Chemicals and Drugs systems to ensure quality throughout the chain
Global Applied Technology Innovation Strategies
Nature of Business: Performance & Life Science Chemicals Subir Basak Exploring the viability of biobetters
• R&D and Process Development – gain in-depth guidance on advanced cloning, Merck KGaA CEO and biosuperiors
Number of Employees Annual Turnover Organisation’s Main Area of Business: Celestial Biologicals
fermentation and purification processes and their scale-up, to ensure the quality and safety of Please tick one box Please tick one box Please tick one box Rustam Modi
your biosimilars Chief Scientific Officer, Director Quality Aruna R Khare
50,000 or more More than US$40 Million Biopharma Manufacturer Packaging Supplier Principal Scientist, Incharge, Bioassay
Biotechnology Manufacturer Consultant
Assurance and Immunoassay Laboratory
10,000 - 49,999 US$30 - US$40 Million
Intas Biopharmaceuticals USV
• Manufacturing and Distribution – take advantage of cost-effective cGMP facilities and 5,000 - 9,999 US$20 - US$30 Million Innovator Pharma Manufacturer Regulator
cold- chain management for volume production and distribution of biosimilars 1,000 - 4,999 US$10 - US$20 Million Generic Pharma Manufacturer Academic Institute VK Vinayak UC Banerjee
500 - 999 Less than US$10 Million CRO Trade Association Vice President Research and Development Professor & Head Department of Pharmaceutical
Panacea Biotec Technology, Biotechnology
• Commercialisation – pricing, partnerships and outsourcing strategies to drive the early 250 - 499 CMO Media
NIPER
100 - 249 Analytical Laboratory Sanjay Singh
profitability of your biosimilars business CEO Samir Sangitrao
1 to 99 Ingredient Supplier
Gennova Biopharmaceuticals Head Regulatory Affairs
Intas Biopharmaceuticals
• Biobetters and Biosuperiors – pave the way today to reap the longer term rewards of the How to pay Bookings received less than thirty days before the conference date can only be paid by credit card Vikram Paradkar
biologics market in India Vishwanath B Malkar
Vice President Biotechnology Head Regulatory and Quality
Terms & Conditions: It may be necessary due to unforeseen Reliance Life Sciences Reliance Life Sciences
Cheque circumstances to alter the content, timing, speakers or venue. This
contract is subject to Mumbai Jurisdiction law. Vijay Kshirsagar Krishnamohan B
We have assembled an outstanding line-up of industry leading speakers including senior Fees: Conference fees include entrance to the conference Executive Vice President, General Manager Operations,
Please find enclosed a cheque for the amount of INR US$
representatives of: Merck KGaA, Intas Biopharmaceuticals, Wockhardt, Panacea Biotec, sessions, refreshments as per onsite schedule, and the conference
Corporate Quality Assurance Biotech Division
made payable to UBM India Pvt. Ltd. Please send to address above (in WAYS TO REGISTER box) papers. Fees are subject to applicable taxes as per government
Lupin Pharmaceuticals, Gennova Biopharmaceuticals, Reliance Life Sciences, USV, rules and regulations. Please note that accommodation and travel and Regulatory Affairs Lupin Pharmaceuticals
Shasun Chemicals and Drugs, Unichem Laboratories, plus many more… are not included in the conference fee. Unichem Laboratories Hareesh Parandhaman
Bank Transfer Substitutions: Once booked cancellation of delegate places Head Business Development,
Anand Kumar
can not be made, however substitution can be made at any time.
Associate Vice Biotechnology
Don’t delay! Call us today to secure your place at the only Biosimilars conference focused on the Please email details of the substitute delegate to Lupin Pharmaceuticals
Email (accounts contact) conferences@ubmindia.com at the earliest opportunity. President, Quality
opportunities and challenges of the Indian market specifically! Invoice Address (if different from above Accommodation: Orbitz are the officially appointed accom- Wockhardt plus many more...
modation agency. Orbitz have secured allocations at conveniently
Booking is easy! Just call us on +91 (022) 4046 1466, email conferences@ubmindia.com or Purchase Order No. (where applicable) located hotels to the venue at discounted event rates. These rates
are held for a limited amount of time, please book early to avoid
To pay by bank transfer please send payments to: HSBC Bank, 52/60, MG Road, Fort Mumbai, 400 001, India. Beneficiary Name: UBM India
visit www.biosimilars-india.com Pvt Ltd. Type of Account: Current. MICR No: 400039002. IFSC Code: HSBC0400002. Swift Code: HSBCINBB. Bank Code/Bank ID: 039. Branch disappointment. Call +91 (0)22 2410 2801/2/3 or
Code: 002. For INR and USD payments Account Number: 002-859882-004. Please fax a copy with delegate(s) and conference name of your email miceindia@orbit-elite.com
bank transfer to +91 (0)22 4046 1477. Please note that invoice will be sent separately. For invoice queries call: +91 (0)22 4046 1466. Data Protection: By entering your details in the fields above,
I look forward to seeing you at the event in September. you agree to allow UBM India Pvt Ltd. and companies associated
Credit Card/Debit Card with the event to contact you (by post, telephone, sms, email or
fax) regarding relevant products or services provided. If at any
Best wishes, Please debit my:
time you do not wish to receive anything from i) UBM India Pvt
Ltd. or ii) carefully selected 3rd parties, please write to Manoj Organised by Media Partners
Card No: Expiry Date:
Ambardekar, Database Manager, UBM India Pvt Ltd. Sagar Tech
Issue No (for Maestro) Valid From: Amount: Security Code: Plaza A, 119, 1st Floor, Andheri Kurla Road, Saki Naka Junction,
Andheri East, Mumbai, 400072, India. Or
Niyoti Trivedi Vyas Card Holder’s Name:
email manoj.ambardekar@ubm.com for more information.
Programme Manager Billing Address
Service Tax Registered No. AAACU8181DST001
CPhI Conferences Issuing Bank
Signature:
*I have read the cancellation policy and agree with the terms and conditions. I authorise my credit/debit card for the above payment Customer Code: Web To register - Tel +91 (022) 4046 1466, Fax +91 (022) 4046 1477, Email conferences@ubmindia.com
www.biosimilars-india.com